Low-dose combination of perindopril arginine with indapamide in correction of metabolic syndrome

Abstract


Aim. To study ways of realization of pleiotropic effects of treatment with low-dose combination of perindopril arginine with indapamide in hypertensive patients with metabolic syndrome (MS).
Material and methods. Thirty hypertensive patients with MS received low-dose combined drug noliprel A (Servier, France). In weak hypotensive effect noliprel A forte was used. An antihypertensive (by the data of 24-h blood pressure monitoring), sympatholytic (by the levels of ACTH and cortisol in blood plasma, by variability of the heart rate)and metabolic effects of the drug were assessed after 3 weeks, 3 and 6 months of treatment.Carbohydrate metabolism was studied by glucose and insulin blood levels before meal and after it. Lipid and purin metabolism were assessed by enzyme method, leptin levels - by enzyme immunoassay.
Results. 24-h blood pressure monitoring registered a stable regular blood pressure lowering, target blood pressure was achieved in 78.6% patients. Blood ACTH concentration significantly reduced showing a sympatholytic action of the drug.Parameters of lipid, carbohydrate and purin metabolism changed insignificantly. Positive changes were seen in anthropometric indices, leptin tended to decrease. Changes in these parameters, sympatholytic and hypotensive effects depended on plasmic levels of leptin.
Conclusion. A fixed low-dose combination of perindopril arginine with indapamide in a stable hypotensive effect and metabolic neutrality influences some key components of MS including hyperactivity of sympathic autonomic nervous system component and hyperleptinemia.

About the authors

Svetlana Igorevna Kseneva

Email: viksbest@mail.ru

Elena Valentinovna Borodulina

Tat'yana Aleksandrovna Semiglazova

Natal'ya Vadimovna Kulakova

Irina Vadimovna Tarasova

Vladimir Vasil'evich Udut

S I Kseneva

Research Institute of Pharmacology of AMS Siberian Section, Tomsk

Research Institute of Pharmacology of AMS Siberian Section, Tomsk

E V Borodulina

Research Institute of Pharmacology of AMS Siberian Section, Tomsk

Research Institute of Pharmacology of AMS Siberian Section, Tomsk

T A Semiglazova

Research Institute of Pharmacology of AMS Siberian Section, Tomsk

Research Institute of Pharmacology of AMS Siberian Section, Tomsk

N V Kulakova

Research Institute of Pharmacology of AMS Siberian Section, Tomsk

Research Institute of Pharmacology of AMS Siberian Section, Tomsk

I V Tarasova

Research Institute of Pharmacology of AMS Siberian Section, Tomsk

Research Institute of Pharmacology of AMS Siberian Section, Tomsk

V V Udut

Research Institute of Pharmacology of AMS Siberian Section, Tomsk

Research Institute of Pharmacology of AMS Siberian Section, Tomsk

References

  1. Константинов B. O., Сайфулина Я. Р. Метаболический синдром - болезнь или случайный набор риск-факторов? Артер. гипертензия 2007; 13(3): 195-196.
  2. Ford E. S. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U. S. Diabet. Care 2005; 28: 2745-2749.
  3. Адашева T. B., Демичева О. Ю. Метаболический синдром - основы патогенетической терапии. Лечащий врач 2003; 10: 24-28.
  4. Конради А. О. Ожирение, симпатическая гиперактивность и артериальная гипертензия - есть ли связь? Артер. гипертензия 2006; 12(2): 2-9.
  5. Bell-Anderson К. S., Bryson J. М. Leptin as a potential treatment for obesity: progress to date. Treat. Endocrinol. 2004; 3: 11-18.
  6. Daskalopoulou S. S., Mikhailidis D. P., Elisaf M. Prevention and treatment of metabolic syndrome. Angiology 2004; 55(6): 589-612.
  7. Оганов Р. Г., Мамедов M. H., Колтунов И. Е. Метаболический синдром: путь от научной концепции до клинического диагноза. Врач 2007; 3: 3-7.
  8. Чазова И. Е., Мычка В. Б. Метаболический синдром. М.: Медиа Медика; 2004.
  9. Бригов А. Н. Современные подходы к лечению артериальной гипертонии: учет других факторов риска и ассоциированных заболеваний. Трудный пациент 2006; 8: 65-70.
  10. Котовская Ю. В. Метаболический синдром: прогностическое значение и современные подходы к комплексной терапии. Сердце 2005; 4 (5): 236-241.
  11. Meigs J. B., Wilson W. F., Nathan D. M. et al. Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring studies. Diabetes 2003; 52: 2160-2167.
  12. Grundy S. M. Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. Nat. Rev. Drug Discov. 2006; 5: 295-309.
  13. Giverts M. M. Manipulation of the renin-angiotensin system. Circulation 2001; 104(5): 14-18.
  14. Митченко Е. И. Метаболический синдром: состояние проблемы и лечебные подходы. Практична ангiол. 2006; 1: 14-18.
  15. Кобалава Ж. Д. Место комбинированной антигипертензивной терапии в современном лечении артериальной гипертонии. Клин. фармакол. и тер. 2001; 10(3): 1-5.
  16. Моисеев С. В. Симпатическая нервная система и метаболический синдром. Клин. фармакол. и тер. 2004; 4: 70-74.
  17. Eikelis N., Esler М. The neurobiology of human obesity. Exp. Physiol. 2005; 90(5): 673-682.
  18. Миронова T. B., Миронов B. A. Клинический анализ волновой структуры синусового ритма сердца. Челябинск; 1998.

Statistics

Views

Abstract - 133

Cited-By


Article Metrics

Metrics Loading ...

Refbacks

  • There are currently no refbacks.

Copyright (c) 2011 Kseneva S.I., Borodulina E.V., Semiglazova T.A., Kulakova N.V., Tarasova I.V., Udut V.V., Kseneva S.I., Borodulina E.V., Semiglazova T.A., Kulakova N.V., Tarasova I.V., Udut V.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:

 

© 2018 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies